-
2024-512803-37-00
5
2022-10-05
Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)
-
2024-513635-24-00
10
2022-09-29
oesophageal cancer
-
2024-513992-42-00
10
2022-09-13
venous thromboembolism (VTE) in patients with gastrointestinal/genitou
-
2024-513859-33-00
5
2022-08-26
Glycogen storage disease type II
-
2024-512791-36-00
4
2022-08-24
Treatment of moderate-to-severe Atopic dermatitis
-
2023-509569-19-00
10
2022-08-10
venous thromboembolism (VTE)
-
2022-501132-42-00
6
2022-08-02
Monkeypox virus disease
-
2023-510110-36-00
5
2022-07-11
Hypereosinophilic syndrome (HES)
-
2023-508357-58-00
7
2022-07-04
Acute lymphocytic leukaemia- Acute myeloid leukaemia refractory - Myel
-
2023-507569-24-00
4
2022-06-20
Myocardial Infarction, Acute
Heart Failure, Left Sided
-
2023-507634-24-00
5
2022-05-20
Improper function of certain messenger materials in the body that cont
-
2023-509139-16-00
5
2022-05-13
Therapeutic confirmatory (phase III)
-
2023-509784-24-00
4
2022-05-11
Idiopathic Pulmonary Fibrosis
-
2024-511996-13-00
5
2022-05-11
Previously untreated, unresectable, or metastatic melanoma
-
2024-512639-58-00
7
2022-05-07
Solid Tumors
-
2024-511810-18-00
5
2022-04-19
End stage chronic kidney disease (CKD) patients who are highly sensiti
-
2024-513304-33-00
5
2022-03-17
Type 1 diabetes mellitus
-
2024-510696-38-00
5
2022-03-08
Severe Hypertriglyceridemia.
-
2024-510722-10-00
7
2021-12-13
Malignant Solid Tumors
-
2024-515821-27-00
9
2021-11-30
Prostate Cancer
-
2024-513573-49-00
6
2021-11-03
Burn injury
-
2024-512345-16-00
4
2021-10-13
Chronic inflammatory demyelinating polyradiculoneuropathy
-
2023-506926-35-00
5
2021-09-24
Atherosclerotic cardiovascular disease, chronic kidney disease and sys
-
2023-503813-31-01
5
2021-09-17
Second- or Third-Line Recurrent or Metastatic Cervical Cancer